The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605494592 | ||
| 003 | CHVBK | ||
| 005 | 20210128100526.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151001xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s00261-015-0547-0 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s00261-015-0547-0 | ||
| 245 | 0 | 4 | |a The ability of 18F-choline PET/CT to identify local recurrence of prostate cancer |h [Elektronische Daten] |c [Laura Evangelista, Marino Cimitan, Marina Hodolič, Tanja Baseric, Jure Fettich, Eugenio Borsatti] |
| 520 | 3 | |a Purpose: To determine when 18F-choline PET/CT can truly identify local recurrence of prostate cancer. Methods: 1031 patients from 3 European centers underwent 18F-choline PET/CT (FCH PET/CT) for recurrent disease; 131 subjects (12.7%) showed a positive FCH uptake in the prostatic gland or prostatic fossa. Median age was 72years (range 48-87years), and the median PSA level at the time of FCH PET/CT scan was 4.41ng/mL (0.22-18.13ng/mL). 45 patients (34.4%) had a Gleason score (GS) >7, and the residual subjects had a GS ≤7. The assessment of true or false-positive FCH PET/CT findings was made by magnetic resonance imaging (n=34) and/or biopsy in 75/131 cases. A χ 2 test and a Z Kolmogorov-Smirnov test were used to assess the correlation between clinical variables (age, PSA, GS, type of therapy) and FCH PET/CT findings. Results: FCH PET/CT resulted truly positive (TP) for recurrent disease in the prostatic gland/fossa in 59/75 patients (79%) and falsely positive (FP) in 16 subjects (21%). The median value of PSA at the time of FCH PET/CT scan was higher in TP as compared to FP, although not statistically significant (4.76 vs. 3.04ng/mL p>0.05). Similarly, median age, GS categories, and the type of therapy were similar between the two groups (p>0.05). However, when matching GS categories and PSA values, we found that the number of patients with TP findings were higher in the case of a PSA >2ng/mL, independently from the GS (ranging between 74% and 92%). Conversely, FP rate ranged between 50% and 65% in patients with a PSA ≤2ng/mL, especially in the case of GS ≤7, whereas FP was around 25% in those with a GS >7 and PSA >2ng/mL. Conclusions: FCH PET/CT has a limited role in evaluation of prostatic gland/fossa recurrence, due to the physiological biodistribution of the radiopharmaceutical agent. However, in 70-90% of patients with a PSA >2ng/mL, independently from GS, a focal FCH uptake is compatible with a true local recurrence. | |
| 540 | |a Springer Science+Business Media New York, 2015 | ||
| 690 | 7 | |a Prostate cancer recurrence |2 nationallicence | |
| 690 | 7 | |a 18F-choline PET/CT |2 nationallicence | |
| 690 | 7 | |a False positive |2 nationallicence | |
| 690 | 7 | |a True positive |2 nationallicence | |
| 690 | 7 | |a Salvage treatments |2 nationallicence | |
| 700 | 1 | |a Evangelista |D Laura |u Radiotherapy and Nuclear Medicine Unit, Veneto Institute of Oncology IOV - IRCCS, Via Gattamelata, 64, 35128, Padua, Italy |4 aut | |
| 700 | 1 | |a Cimitan |D Marino |u Nuclear Medicine Unit, IRCCS National Cancer Institute (CRO), Aviano, PN, Italy |4 aut | |
| 700 | 1 | |a Hodolič |D Marina |u Nuclear Medicine Research Department, IASON, Graz, Austria |4 aut | |
| 700 | 1 | |a Baseric |D Tanja |u Nuclear Medicine Unit, IRCCS National Cancer Institute (CRO), Aviano, PN, Italy |4 aut | |
| 700 | 1 | |a Fettich |D Jure |u Nuclear Medicine Department, University Medical Center Ljubljana, Ljubljana, Slovenia |4 aut | |
| 700 | 1 | |a Borsatti |D Eugenio |u Nuclear Medicine Unit, IRCCS National Cancer Institute (CRO), Aviano, PN, Italy |4 aut | |
| 773 | 0 | |t Abdominal Imaging |d Springer US; http://www.springer-ny.com |g 40/8(2015-10-01), 3230-3237 |x 0942-8925 |q 40:8<3230 |1 2015 |2 40 |o 261 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00261-015-0547-0 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s00261-015-0547-0 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Evangelista |D Laura |u Radiotherapy and Nuclear Medicine Unit, Veneto Institute of Oncology IOV - IRCCS, Via Gattamelata, 64, 35128, Padua, Italy |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Cimitan |D Marino |u Nuclear Medicine Unit, IRCCS National Cancer Institute (CRO), Aviano, PN, Italy |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hodolič |D Marina |u Nuclear Medicine Research Department, IASON, Graz, Austria |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Baseric |D Tanja |u Nuclear Medicine Unit, IRCCS National Cancer Institute (CRO), Aviano, PN, Italy |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Fettich |D Jure |u Nuclear Medicine Department, University Medical Center Ljubljana, Ljubljana, Slovenia |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Borsatti |D Eugenio |u Nuclear Medicine Unit, IRCCS National Cancer Institute (CRO), Aviano, PN, Italy |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Abdominal Imaging |d Springer US; http://www.springer-ny.com |g 40/8(2015-10-01), 3230-3237 |x 0942-8925 |q 40:8<3230 |1 2015 |2 40 |o 261 | ||